Pacific Biosciences

BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer

Retrieved on: 
Wednesday, November 29, 2023
Other Health, Research, General Health, Oncology, Technology, Genetics, Science, Cardiology, Neurology, Other Technology, Other Science, Health, Pacific Biosciences, Molecular biology, Genomics, Multimedia, Doctor of Philosophy, Marketing, University, Cancer, Growth, CCO, Single-cell analysis, Management, Illumina

BioSkryb Genomics , a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.

Key Points: 
  • BioSkryb Genomics , a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.
  • Dr. Laxman will lead sales and support, commercial strategy and operations, and marketing as BioSkryb continues to scale its global presence.
  • View the full release here: https://www.businesswire.com/news/home/20231129687097/en/
    BioSkryb has appointed Ram Laxman, Ph.D., as Chief Commercial Officer.
  • (Photo: Business Wire)
    Dr. Laxman joins BioSkryb from 10x Genomics, where he served as the President and General Manager, APAC.

Global Cancer Microbiome Sequencing Market Landscape 2023-2027: Decreasing Sequencing Costs, Rise in Research & Development - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Oncology, Pacific Biosciences, QIAGEN, Prevalence, Biotechnology, Cancer, Diagnosis, Breast, Research, OraSure Technologies, Biomarker, Lung, Death, Incidence, Investment, Polymerase chain reaction, Clifton Springs Hospital & Clinic, Growth, WHO, Geography, Eurofins Scientific, Skin, World Health Organization, Oxford Nanopore Technologies, Software, Antibiotics, Medical imaging, Pharmaceutical industry, Illumina

The global cancer microbiome sequencing market is poised for remarkable growth during the forecast period from 2023 to 2027.

Key Points: 
  • The global cancer microbiome sequencing market is poised for remarkable growth during the forecast period from 2023 to 2027.
  • Decreasing Sequencing Costs: The cost of microbiome sequencing is reducing, making it more accessible for research and clinical applications.
  • Rise in Research & Development: Increasing research efforts aimed at understanding the impact of microbiomes on cancer have propelled the market.
  • Conclusion: With the convergence of growing cancer incidences, increasing awareness of microbiome contributions, and research advancements in sequencing technologies, the global cancer microbiome sequencing market is set for substantial growth.

Element Biosciences Announces Genomics Industry Veteran as Senior Vice President of Marketing and Product Management

Retrieved on: 
Thursday, July 13, 2023
Psychology, University of California, San Diego, Pacific Biosciences, Applied Biosystems, University, Marketing, Genomics, Agriculture, Abraxis BioScience, Business administration, SAN, Element, RS, Biology, Management

SAN DIEGO, July 13, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the appointment of Edwin Hauw as senior vice president of marketing and product management.

Key Points: 
  • SAN DIEGO, July 13, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the appointment of Edwin Hauw as senior vice president of marketing and product management.
  • "The genomics industry is at a crucial inflection point, and Element has brought innovative technologies to cutting-edge labs across the world," said Molly He, Ph.D., CEO and Co-founder of Element Biosciences.
  • As senior vice president of marketing and product management, Edwin will work along with the leadership team to evolve, guide and manage product strategy, strategic marketing, field marketing and product management.
  • Edwin was previously 10x Genomics' vice president of marketing, leading product management and marketing and growing the business by 20x within his six years.

PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030

Retrieved on: 
Monday, June 26, 2023
Pacific Biosciences, Abraxis BioScience, Debt-to-GDP ratio, Bids for the 2024 and 2028 Summer Olympics, Goldman Sachs, Growth, Security (finance), Note, News & Notes

"In 2021, we issued $900 million in convertible notes due in 2028, enabling us to scale the company for growth.

Key Points: 
  • "In 2021, we issued $900 million in convertible notes due in 2028, enabling us to scale the company for growth.
  • In exchange for issuing the New Notes pursuant to the Exchange Transaction, PacBio will receive and cancel the exchanged 2028 Notes.
  • Following the closing of the Exchange Transaction, $459 million in aggregate principal amount of 2028 Notes will remain outstanding with terms unchanged.
  • Goldman Sachs & Co. LLC acted as exclusive financial advisor to PacBio in connection with the Exchange Transaction.

Prof. Roger D. Kornberg, Chemistry Nobel laureate, will be joining Tissue Dynamics' advisory board

Retrieved on: 
Wednesday, May 31, 2023
Pacific Biosciences, Teva Pharmaceuticals, Plague, Fatty liver disease, Drug development, Therapy, Bionics, Immunotherapy, Stanford University, Abbott, Chromatin, Cardiovascular disease, Food and Drug Administration Modernization Act of 1997, Dynamix, Research, RNA, Chemistry, Algorithm, Nobel, Drug discovery, Biology, FDA, Pharmaceutical industry, Merck

With previous experience serving on the advisory boards of Pacific Biosciences and Teva Pharmaceuticals, Prof. Kornberg is expected to provide invaluable insights to Tissue Dynamics.

Key Points: 
  • With previous experience serving on the advisory boards of Pacific Biosciences and Teva Pharmaceuticals, Prof. Kornberg is expected to provide invaluable insights to Tissue Dynamics.
  • "We are honored to welcome Prof. Kornberg to our advisory board," said Professor Yaakov Nahmias, founder and Chairman of Tissue Dynamics.
  • Prof. Kornberg expressed, "I am honored to join the advisory board of Tissue Dynamics and look forward to contributing to its success.
  • Prof. Kornberg's expertise is expected to significantly contribute to Tissue Dynamics' success in achieving its goal of transforming drug development.

Global Functional Genomics Market Report 2023: Sector is Expected to Reach $46.24 Billion by 2033 at a CAGR of 14.04% - ResearchAndMarkets.com

Retrieved on: 
Friday, May 26, 2023
Health, Genetics, Pacific Biosciences, Symphogen, DNA, BIS, Partnership, Workflow, Epigenomics, Research, Thermo Fisher Scientific, Genomics, RNA, Proteomics, Protein, Data analysis, Oxford Nanopore Technologies, Laboratory, Illumina, Inc., Metabolomics, Medicine, Growth, Region, Gene, Disease, Genome, Antibiotics

In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033.

Key Points: 
  • In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033.
  • The growth in the global functional genomics market is expected to be driven by its increased applications especially in targeted therapy and precision medicine.
  • Functional genomics is the study of genes and their interactions in different biological processes.
  • According to BIS Research functional genomics products are used in DNA level (epigenomics), RNA level (transcriptomics), protein level (proteomics) or metabolite level (metabolomics).

Zymo Research launches full-length 16S sequencing service to revolutionize microbiome research

Retrieved on: 
Wednesday, May 17, 2023
Pacific Biosciences, Metagenomics, Partnership, Senior, Abraxis BioScience, NGS, Business, Research, Doctor of Philosophy, Emerging market, Microbiology, Antibiotics

IRVINE, Calif., May 17, 2023 /PRNewswire/ -- Zymo Research , a leading provider of microbiology research tools, has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.

Key Points: 
  • IRVINE, Calif., May 17, 2023 /PRNewswire/ -- Zymo Research , a leading provider of microbiology research tools, has officially launched its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis.
  • Zymo Research is releasing this new service using the latest sequencing platforms by Pacific Biosciences (PacBio).
  • "We are excited to offer our Full-Length 16S Sequencing Service to the microbiome scientific community," said Marc Van Eden, PhD, VP of Business Development at Zymo Research.
  • In addition to launching its Full-Length 16S Sequencing Service, Zymo Research has become one of PacBio's preferred certified service providers.

Clearwater Analytics Announces First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 4, 2023
Pacific Biosciences, Private banking, Clearwater Analytics, Royal Neighbors of America, Software as a service, Elastic, Fintech, Plug Power, Robinhood Markets, Bank of America Private Bank, EBITDA, Acquisition, Investment, ACV, ARR, UBS, Knowledge, Bank, Merrill (company), NYSE, Video game, Cryptocurrency

BOISE, Idaho, May 4, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. (NYSE: CWAN) ("Clearwater Analytics" or the "Company"), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced its financial results for the quarter ended March 31, 2023.

Key Points: 
  • Record Quarterly Revenue of $84.6 Million, Up 20% Year-Over-Year
    BOISE, Idaho, May 4, 2023 /PRNewswire/ -- Clearwater Analytics Holdings, Inc. (NYSE: CWAN) ("Clearwater Analytics" or the "Company"), a leading provider of SaaS-based investment accounting, reporting, and analytics solutions, today announced its financial results for the quarter ended March 31, 2023.
  • Revenue: Total revenue for the first quarter of 2023 reached $84.6 million, an increase of 19.5%, from $70.8 million in the first quarter of 2022.
  • Results for the first quarter of 2023 reflect the JUMP Technology acquisition that closed in December 2022.
  • Gross Profit: Gross profit for the first quarter of 2023 was $59.8 million, compared with $49.6 million in the first quarter of 2022.

Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments

Retrieved on: 
Monday, April 24, 2023
Semiconductor, Health, Technology, Health Technology, Genetics, Pharmaceutical, Biotechnology, Hamamatsu Photonics, Pacific Biosciences, Reagent, Operation, Protein sequencing, Senior, Data science, Marketing, Chief commercial officer, Algorithm, Autocar Sales and Service Building, University of California, Santa Cruz, Oxford Nanoimaging, Research, Genomics, Dicarboxylic acid, Doctor of Philosophy, Proteomics, Protein, UC, Engineering, Epic Sciences, Raytheon Technologies, Drug discovery, Supply, Corisella inscripta, Genetix, Platinum, Management, Fine chemical, Illumina

These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.

Key Points: 
  • These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.
  • Prior to this, Ms. Atkinson held executive leadership positions at Truvian, Epic Sciences, Edico Genome and Illumina.
  • Mr. Hutcheson has more than 20 years of experience as a commercial professional within the genomics, biotechnology, and drug discovery markets.
  • Its elegant simplicity enables broad-scale access to proteomic data, making it a critical instrument for the future of proteomics research.

GeneCentric Therapeutics Appoints Brian Kelly as SVP Business Development

Retrieved on: 
Wednesday, April 12, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Pacific Biosciences, Business development, Senior, Johns Hopkins School of Medicine, Life Technologies, Thermo Fisher Scientific, IP, RNA, Doctor of Philosophy, Towson University, Tempus, Johns Hopkins University, Physician, Medicine, Biology, Therapy, Labcorp, Affymetrix, Management

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development.
  • Mr. Kelly will be responsible for spearheading the Company’s global business growth strategy, with a focus on diagnostic partnering and biopharmaceutical alliance programs and other corporate development initiatives to advance the Company’s strategic priorities.
  • A business leader in cancer research and genomic analysis technologies, Mr. Kelly has more than 15 years’ experience in global business and market development, companion diagnostics and biomarker strategies.
  • Prior to that, he held various clinical market development and commercial roles at Life Technologies, Pacific Biosciences and Affymetrix.